Communiqués Kintor Pharmaceutical Limited

Actions

9939

KYG5273B1077

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:42 28/06/2024			Varia. 5j.	Varia. 1 janv.
1,04 ^HKD	-4,59%		-7,96%	-36,20%

20/06	Kintor Pharmaceutical Limited annonce le départ à la retraite d'administrateurs et la modification de la composition du comité d'audit	CI
17/06	Kintor Pharmaceutical a terminé le recrutement du premier sujet dans un essai clinique de phase 2 d'un médicament contre l'acné en Chine	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Kintor Pharmaceutical : Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine	28/10/23	PU
Kintor Pharmaceutical : Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China	11/10/23	PU
Kintor Pharmaceutical : Pharma Announces 2023 Interim Results and Recent Business Highlights	28/08/23	PU
Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China	22/08/23	PU
Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA	20/07/23	AQ
Kintor Pharmaceutical : Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US	11/05/23	PU
Kintor Pharmaceutical : Pharma Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematologic Malignancies in China	08/05/23	PU
Kintor Pharmaceutical : Pharma Announces Completion of Phase I Clinical Trial of GT20029 in the US	18/04/23	PU
Kintor Pharmaceutical : Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China	14/04/23	PU
Kintor Pharma Announces 2022 Annual Results and Recent Business Progress	30/03/23	PR
Kintor Pharmaceutical : Pharma Announces 2022 Annual Results and Recent Business Progress	30/03/23	PU
Kintor Pharmaceutical : Pharma Announces Preclinical Data of GT1708F at AACR 2023	16/03/23	PU
Kintor Pharmaceutical : Pharma Announced Completion of Phase I Trial of the World’s First PROTAC Compound (GT20029) for Topical Use	24/11/22	PU
Kintor Pharmaceutical : Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual c-Myc/GSPT1 Degrader GT19715	10/11/22	PU
Kintor Pharmaceutical : Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US	27/10/22	PU
Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Acne Vulgaris in China	16/10/22	PU
Kintor Pharmaceutical : Phase Ib Data of GT0918 for AR+ mBC Published in EJC	29/09/22	PU
Kintor Pharmaceutical : Pharma Roadshow Presentation	30/08/22	PU
Kintor Pharmaceutical : Pharma Announces 2022 Interim Results and Recent Business Highlights	29/08/22	PU
Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US	03/08/22	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Kintor Pharmaceutical Limited

Actions

9939

KYG5273B1077

Communiqués

Filtres